Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia : A multicenter real‐world study

作者：Yuqian Sun, Lixin Wu, Yicheng Zhang, Ya‐Jing Xu, Xiaobing Huang, Xiao‐Bing Huang, Bao‐Dong Ye, Hailong Yuan, Jianying Zhou, Sujun Gao, Fang Zhou, Yue Liu, Xianmin Song, Yu Cai, Xiao‐Liang Liu, Yi Luo, Lu‐Xin Yang, Jianmin Yang, Libing Wang, Yuhua Li, Rui Huang, Shun‐Qing Wang, Ming Zhou, Yu‐Jun Dong, Qian Wang, Yimei Feng, Xi Zhang, Xi Zhang, Xin Du, Ling Wei, Han Zhu, Zunmin Zhu, Xiang‐Li Chen, Shiyu Wang, Fankai Meng, Kehong Bi, Ning Huang, Ming Jiang, Ting Niu, Jie Ji, Dingming Wan, Zhilei Bian, Yi Chen, Li Liu, Xue‐Qian Yan, Xi Yang, Hai Yi, Xudong Wei, Xin Li, Qian Cheng, Chenglu Yuan, Wen Wang, Yuhong Zhou, Yuhong Chen, Feng‐Rong Wang, Yuanyuan Zhang, Zhidong Wang, Xiao‐Dong Mo, Wei Han, Jing‐Zhi Wang, Yu Wang, Huan Chen, Xiang‐Yu Zhao, Ying‐Jun Chang, Kai‐Yan Liu, Jia Feng, Lan‐Ping Xu, Hongyu Zhang, Xiao‐Jun Huang, Xiao‐Jun Huang, Xiaohui Zhang, Xiaohui Zhang · 发表于：International Journal of Cancer · 年份：2025 · DOI：10.1002/ijc.35485 · 被引用次数：5 · 研究领域：Acute Myeloid Leukemia Research、Hematopoietic Stem Cell Transplantation、Immune Cell Function and Interaction

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative strategy for patients with chronic myelomonocytic leukemia (CMML). However, few reports have investigated the outcomes of patients receiving haploidentical HSCT. To this end, we included 117 patients with haploidentical donors (HID) and 75 patients with matched related donors (MRD) from 28 centers across China to explore the prognostic impact of different transplantation modalities. We found no significant difference between these two groups in terms of event-free survival (EFS, p = .211), overall survival (OS, p = .503), cumulative incidence of relapse (CIR, p = .076) or non-relapse mortality (NRM, p = .794). The predominance of peripheral blood (PB) graft source over bone marrow and PB since 2020 may have contributed to the worse outcomes in the MRD group. Moreover, CMML-specific prognostic scoring system (CPSS) lower-risk patients benefited more from the HID modality with superior EFS (p = .006). Multivariate analysis indicated that advanced age (p = .013), anemia at diagnosis (p = .010), and donor relationship (parent-to-child, p = .013) were independently associated with worse EFS in the HID group. Our data suggested that HID was comparable to MRD in CMML. However, under certain conditions, such as CPSS lower-risk ones, HID was preferred.